Commentary

Could lung ultrasound be used instead of auscultation?

The covid-19 era poses significant and unprecedented challenges for re-organisation of care, redistribution of resources and rationing of services [1,2]. A review of patients’ clinical characteristics showed a high prevalence of respiratory symptoms and respiratory failure which require full assessment [3]. However, the role for auscultation is not proven and may be a very risky strategy as the risk of cross infection with taking a stethoscope from a patient to the next is very tangible [4,5]. A recent editorial in the African Journal of Emergency medicine suggested Severity Scoring Tool for low resourced settings and mentioned auscultation [6].

The stethoscope and auscultation have limited usefulness in the assessment of respiratory failure. Crackles on auscultation have a sensitivity of 19–67% and a specificity of 36–96%, with a positive likelihood ratio of 2.3 and a negative likelihood ratio of 0.8 [7]. Thus, their use in ruling pneumonia in or out is limited as their presence or absence only slightly changes the initial diagnosis (poor inter observer reliability, 72% agreement, kappa value 0.41) [7]. One might argue on the value of detecting wheeze on auscultation. The Centers for Disease Control and Prevention (CDC) does not mention wheeze as a symptom of Covid-19 [8]. Furthermore, Xu et al. did not describe wheeze as a finding in 62 patients with Covid-19 [9] and as such wheeze does not seem to be present in such patients.

Hence, in the current pandemic, is there a role for other diagnostic or investigative modalities such as lung ultrasound?

Lung ultrasonography in acute respiratory failure has been described for over a decade. A 2008 single centre study of bedside lung ultrasound examination protocol showed an accuracy of 90.5% in diagnosing the cause of acute respiratory failure in critically ill patients. The methods were standardised and reproducible [8]. This has been since incorporated in consensus guidelines [10]. As such, it has been debated as to whether lung ultrasound can have a role to play in the diagnostic pathway for Covid-19. Point of care ultrasound machines can be small, portable and cleaned in between patients [11,12]. Huang et al. performed lung ultrasound on 19 non-critical Covid-19 patients and found them to have specific characteristics (large number of B lines, subpleural pulmonary consolidation and poor blood flow) which were mainly visible in the posterior and inferior areas [13]. Ultrasound missed lesions that were completely intrapulmonary and apical and some of the analysis is only in abstract form. Care must be applied to the analysis of this as this is a pre-print, and not peer-reviewed. Peng et al. found similar findings using a similar 12 zone method but the article lacks details about the clinical characteristics of the patients [14]. Poggiali et al. found strong correlation between similar ultrasound findings and strong correlation between ultrasound and CT scan findings [15].

Soldati et al. propose a standard process for the use of lung ultrasound for COVID-19 patients but so far there have been no studies looking at patient outcomes [16]. Newly designed guidance from the Association of Chartered Physiotherapists in Respiratory Care are laudable and eventual data gathered from the application of lung ultrasound will be crucial [17].

Whilst lung ultrasound has been shown to demonstrate specific characteristics in Covid-19, there is no current evidence for lung ultrasound changing management and affecting patient outcomes. The vast majority of physicians are not trained at lung ultrasound and that might prove a significant barrier for widespread use [11]. Perhaps lung ultrasound may have a role to play in triage of suspected Covid-19 patients in resource limited settings but again this has not been studied or reported. There is also the question of the patients’ expectations to be physically examined that has been studied by lida et al. [18]. As such, leaving the stethoscope behind in the Covid-19 era will signal a significant paradigm shift.

Author’s contribution

The author contributed as follows to the conception or design of the work; the acquisition, analysis, or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content: AA contributed 100%. The author approved the version to be published and agreed to be accountable for all aspects of the work.

Declaration of competing interest

The author declare no conflict of interest.

References

1. Extance Andy. Covid-19 and long-term conditions: what if you have cancer, diabetes, or chronic kidney disease? BMJ 2020;368:m174https://doi.org/10.1136/bmj.m174.
2. Willan J, John K, Jeffrey K, et al. Challenges for NHS hospitals during covid-19 epidemic. BMJ 2020;368:m1117https://doi.org/10.1136/bmj.m1117.
3. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective, study. BMJ 2020;368:m1091https://doi.org/10.1136/bmj.m1091.
4. Buenonso D, Pata D, Chiaretti A. COVID-19 outbreak: less stethoscope, more ultrasound. Lancet Respir Med Mar 20 2020. https://doi.org/10.1016/S2213-2600(20)30120-X. pii: S2213-2600(20)30120-X.
5. Copetti R. Is lung ultrasound the stethoscope of the new millennium? Definitely yes!. Acta Med Acad May 2016;45(1):80–1. https://doi.org/10.5644/am2006.124.
6. Wallis L. COVID-19 severity scoring tool for low resourced settings. Afr J Emerg Med 2020. https://doi.org/10.1016/j.ajem.2020.03.002.
7. Walden A, Smallwood N, Dachsel M, et al. Thoracic ultrasound: it’s not all about the pleura. BMJ Open Respir Res 2018;5:e000354https://doi.org/10.1136/bmjresp-2018-000354.
8. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html, Accessed date: 25 April 2019.
9. Xu X, Wu X, Jiang X, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606https://doi.org/10.1136/bmj.m606.
10. Silva S, Biendel C, Ruiz J, et al. Usefulness of cardiothoracic chest ultrasound in the management of acute respiratory failure in critical care practice. Chest 2013;144:859-65.
[11] Smallwood N, Dachsel M. Point-of-care ultrasound (POCUS): unnecessary gadgetry or evidence-based medicine? Clin Med (Lond) 2018;18(3):219–24. https://doi.org/10.7861/clinmedicine.18-3-219.

[12] https://www.asecho.org/covid-19-resources/cleaning-recommendations-from-ultrasound-manufacturers/, Accessed date: 25 April 2020.

[13] Lichtenstein DA, Malbrain MLNG. Lung ultrasound in the critically ill (LUCI): a translational discipline. Anaesthesiol Intensive Ther 2017;49:430–6. https://doi.org/10.5603/AIT.a2017.0063.

[14] Peng Q, Wang X, Zhang L. Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019–2020 epidemic. Intensive Care Med Mar 12 2020. https://doi.org/10.1007/s00134-020-05996-6.

[15] Poggiali E, Dacrema A, Bastoni D, et al. Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia? Radiology Mar 13 2020:200847 https://doi.org/10.1148/radiol.2020200847.

[16] Soldati G, Smargiassi A, Inchingolo R, et al. Proposal for international standardization of the use of lung ultrasound for patients with COVID-19. J Ultrasound Med 2020. https://doi.org/10.1002/jum.15285.

[17] https://www.acprc.org.uk/Data/Resource_Downloads/PhysioLUSCOVID-19.pdf?date=23/04/2020%2006:11:42, Accessed date: 25 April 2020.

[18] Iida J, Nishigori H. Physical examination and the physician-patient relationship: a literature review. MedEdPublish 2016;5(3):14. https://doi.org/10.15694/mep.2016.000100.

Avinash Aujayeb
Northumbria Healthcare NHS Foundation Trust, Cramlington, Northumberland, UK
E-mail address: avinash.aujayeb@nhct.nhs.uk.